UA47505C2 - Спосіб лікування плоскоклітинного раку ротової порожнини за допомогою антагоністів лейкотриєну - Google Patents
Спосіб лікування плоскоклітинного раку ротової порожнини за допомогою антагоністів лейкотриєну Download PDFInfo
- Publication number
- UA47505C2 UA47505C2 UA99063226A UA99063226A UA47505C2 UA 47505 C2 UA47505 C2 UA 47505C2 UA 99063226 A UA99063226 A UA 99063226A UA 99063226 A UA99063226 A UA 99063226A UA 47505 C2 UA47505 C2 UA 47505C2
- Authority
- UA
- Ukraine
- Prior art keywords
- alkyl
- ethyl
- solvate
- phenyl
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3426996P | 1996-12-13 | 1996-12-13 | |
| US4087497P | 1997-03-21 | 1997-03-21 | |
| PCT/US1997/021953 WO1998025615A1 (en) | 1996-12-13 | 1997-12-02 | Leukotriene antagonists for oral squamous cell carcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA47505C2 true UA47505C2 (uk) | 2002-07-15 |
Family
ID=26710754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA99063226A UA47505C2 (uk) | 1996-12-13 | 1997-02-12 | Спосіб лікування плоскоклітинного раку ротової порожнини за допомогою антагоністів лейкотриєну |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0964683A4 (de) |
| JP (1) | JP2001509142A (de) |
| KR (1) | KR20000069452A (de) |
| CN (1) | CN1245429A (de) |
| AU (1) | AU726215B2 (de) |
| CA (1) | CA2274855A1 (de) |
| EA (1) | EA002742B1 (de) |
| IL (1) | IL130304A0 (de) |
| NO (1) | NO992846L (de) |
| NZ (1) | NZ335922A (de) |
| PL (1) | PL334241A1 (de) |
| TR (1) | TR199901307T2 (de) |
| UA (1) | UA47505C2 (de) |
| WO (1) | WO1998025615A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002009700A1 (en) | 2000-07-28 | 2002-02-07 | Cancer Research Technology Limited | Cancer treatment by combination therapy |
| GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| GB2386836B (en) | 2002-03-22 | 2006-07-26 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| GB2394658A (en) | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
| US8093253B2 (en) * | 2008-03-06 | 2012-01-10 | Hoffmann-La Roche Inc. | Leukotriene B4 inhibitors |
| KR101898879B1 (ko) | 2014-03-05 | 2018-09-14 | 재단법인 진안홍삼연구소 | 홍삼 가공 추출물을 유효성분으로 함유하는 구강편평세포암의 예방, 개선 또는 치료를 위한 조성물 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6372648A (ja) * | 1986-09-16 | 1988-04-02 | Sumitomo Pharmaceut Co Ltd | 新規不飽和脂肪酸誘導体 |
| PH30449A (en) * | 1991-11-25 | 1997-05-28 | Lilly Co Eli | Substituted phenyl phenol leukotriene antagonists |
| CZ276694A3 (en) * | 1991-11-25 | 1995-11-15 | Lilly Co Eli | Process for preparing diphenyl derivative |
-
1997
- 1997-02-12 UA UA99063226A patent/UA47505C2/uk unknown
- 1997-12-02 IL IL13030497A patent/IL130304A0/xx unknown
- 1997-12-02 PL PL97334241A patent/PL334241A1/xx unknown
- 1997-12-02 NZ NZ335922A patent/NZ335922A/xx unknown
- 1997-12-02 CA CA002274855A patent/CA2274855A1/en not_active Abandoned
- 1997-12-02 AU AU78451/98A patent/AU726215B2/en not_active Ceased
- 1997-12-02 CN CN97181730A patent/CN1245429A/zh active Pending
- 1997-12-02 EA EA199900543A patent/EA002742B1/ru not_active IP Right Cessation
- 1997-12-02 EP EP97949709A patent/EP0964683A4/de not_active Withdrawn
- 1997-12-02 WO PCT/US1997/021953 patent/WO1998025615A1/en not_active Ceased
- 1997-12-02 KR KR1019997005275A patent/KR20000069452A/ko not_active Ceased
- 1997-12-02 JP JP52676298A patent/JP2001509142A/ja not_active Ceased
- 1997-12-02 TR TR1999/01307T patent/TR199901307T2/xx unknown
-
1999
- 1999-06-11 NO NO992846A patent/NO992846L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL130304A0 (en) | 2000-06-01 |
| TR199901307T2 (xx) | 1999-08-23 |
| NO992846D0 (no) | 1999-06-11 |
| KR20000069452A (ko) | 2000-11-25 |
| CN1245429A (zh) | 2000-02-23 |
| JP2001509142A (ja) | 2001-07-10 |
| NZ335922A (en) | 2000-12-22 |
| EA002742B1 (ru) | 2002-08-29 |
| WO1998025615A1 (en) | 1998-06-18 |
| AU7845198A (en) | 1998-07-03 |
| AU726215B2 (en) | 2000-11-02 |
| EA199900543A1 (ru) | 2000-02-28 |
| EP0964683A1 (de) | 1999-12-22 |
| EP0964683A4 (de) | 2002-08-14 |
| PL334241A1 (en) | 2000-02-14 |
| NO992846L (no) | 1999-06-11 |
| CA2274855A1 (en) | 1998-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2207333C (en) | Use of nebivolol as an anti-atherogenic | |
| JP6240075B2 (ja) | 骨粗しょう症の治療方法 | |
| US5910505A (en) | Leukotriene antagonists for use in the treatment or inhibition of oral squamous cell carcinoma | |
| KR0161300B1 (ko) | 뼈 손실 예방에 유용한 벤조티오펜 | |
| KR101819567B1 (ko) | 혈관신생-매개된 질환의 치료용 화합물 | |
| JP2011518174A (ja) | エストロゲン受容体に関連する疾患を処置するための化合物及び方法 | |
| JPH11511127A (ja) | 抗腫瘍剤としてのフェノール置換ジホスホネートの使用 | |
| EP3458448B1 (de) | Fasn-hemmer zur behandlung der nicht-alkoholischen steatohepatitis | |
| JP2017535608A (ja) | 癌標的化薬物ビヒクルとしてのリン脂質エーテル類似体 | |
| WO2013130625A1 (en) | Phospho-ester derivatives and uses thereof | |
| JPH07215871A (ja) | 血清コレステロールを減少させるための方法 | |
| JP2005516938A (ja) | イソインジゴ、インジゴおよびインジルビンの誘導体、ならびに癌治療における使用 | |
| UA47505C2 (uk) | Спосіб лікування плоскоклітинного раку ротової порожнини за допомогою антагоністів лейкотриєну | |
| CA2944517C (en) | Method for treating chronic lymphocytic leukemia | |
| US20240139149A1 (en) | Therapeutic uses of urolithin derivatives | |
| TWI717712B (zh) | 新穎化合物及包含其之用於預防或治療肥胖或代謝症候群的藥學組成物 | |
| JPH09169664A (ja) | 分化誘導作用を有する薬剤 | |
| TWI306760B (en) | Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same | |
| CA2794581C (en) | Method of treating osteoporosis | |
| EP1784173A1 (de) | Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat-derivaten | |
| KR20050044582A (ko) | 위식도 역류 질환의 치료를 위한 신규한 용도 | |
| CN116589502B (zh) | 一种四价铂类免疫原性死亡诱导剂及其制备方法与应用 | |
| JP5313971B2 (ja) | 5−置換4,7−ジメトキシ−1,3−ベンゾジオキソール(5−Substituted4,7−dimethoxy−1,3−benzodioxoles)の結腸直腸癌(colorectalcancer)治療用医薬品 | |
| CN106995368B (zh) | 一种非atp竞争性fgfr1抑制剂及其应用 | |
| JPWO2019031425A1 (ja) | 運動ニューロン疾患治療剤 |